Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKaraçin, Cengiz
dc.contributor.authorÖküzoğlu, Berna
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorKeskinkılıç, Merve
dc.contributor.authorKöse Baytemür, Naziyet
dc.contributor.authorYılmaz, Funda
dc.contributor.authorSelvi, Oğuzhan
dc.contributor.authorErdem, Dilek
dc.contributor.authorAvşar, Esin
dc.contributor.authorPaksoy, Nail
dc.contributor.authorDemir, Necla
dc.contributor.authorSezgin Göksu, Sema
dc.contributor.authorTürker, Sema
dc.contributor.authorBayram, Ertuğrul
dc.contributor.authorÇelebi, Abdüssamet
dc.contributor.authorYılmaz, Hatice
dc.contributor.authorKuzu, Ömer Faruk
dc.contributor.authorKahraman, Seda
dc.contributor.authorGökmen, İvo
dc.contributor.authorSakin, Abdullah
dc.contributor.authorAlkan, Ali
dc.contributor.authorNayır, Erdinç
dc.contributor.authorUğraklı, Muzafer
dc.contributor.authorAcar, Ömer
dc.contributor.authorErtürk, İsmail
dc.contributor.authorDemir, Hacer
dc.contributor.authorAslan, Ferit
dc.contributor.authorSönmez, Özlem
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorCelayir, Özde Melisa
dc.contributor.authorKaradağ, İbrahim
dc.contributor.authorKayıkçıoğlu, Erkan
dc.contributor.authorŞakalar, Teoman
dc.contributor.authorÖktem, İlker Nihat
dc.contributor.authorEren, Tülay
dc.contributor.authorErül, Enes
dc.contributor.authorEylemer Mocan, Eda
dc.contributor.authorKalkan, Ziya
dc.contributor.authorYıldırım, Nilgün
dc.contributor.authorErgün, Yakup
dc.contributor.authorAkagündüz, Baran
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorKut, Engin
dc.contributor.authorTeker, Fatih
dc.contributor.authorÇakan Demirel, Burçin
dc.contributor.authorKaraboyun, Kubilay
dc.contributor.authorAlmuradova, Elvina
dc.contributor.authorÜnal, Olçun Ümit
dc.contributor.authorOyman, Abdülkerim
dc.contributor.authorIşık, Deniz
dc.contributor.authorOkutur, Kerem
dc.contributor.authorÖztosun, Buğra
dc.contributor.authorBelen Gülbağcı, Burcu
dc.contributor.authorKalender, Mehmet Emin
dc.contributor.authorŞahin, Elif
dc.contributor.authorSeyyar, Mustafa
dc.contributor.authorÖzdemir, Özlem
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorKanıtez, Metin
dc.contributor.authorDede, İsa
dc.contributor.authorGümüş, Mahmut
dc.contributor.authorGökmen, Erhan
dc.contributor.authorYaren, Arzu
dc.contributor.authorMenekşe, Serkan
dc.contributor.authorEbinç, Senar
dc.contributor.authorAksoy, Sercan
dc.contributor.authorİnanç İmamoğlu, Gökşen
dc.contributor.authorAltınnbaş, Mustafa
dc.contributor.authorÇetin, Bülent
dc.contributor.authorOyan Uluç, Başak
dc.contributor.authorEr, Özlem
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorErdoğan, Atike Pınar
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorTanrıverdi, Özgür
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorOktay, Esin
dc.contributor.authorBayoğlu, İbrahim Vedat
dc.contributor.authorPaydaş, Semra
dc.contributor.authorAydıner, Adnan
dc.contributor.authorKıvrak Salim, Derya
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorYavuzşen, Tuğba
dc.contributor.authorDoğan, Mutlu
dc.contributor.authorHacıbekiroğlu, İlhan
dc.date.accessioned2023-04-18T09:05:16Z
dc.date.available2023-04-18T09:05:16Z
dc.date.issued2023en_US
dc.identifier.citationKaracin, C., Öksüzoğlu, B., Demirci, A., Keskinkılıç, M., Köse Baytemür, N., Yılmaz, F., ... & Göksu, S. S. (2023). Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (BMC cancer (2023) 23 1 (136)). BMC Cancer.en_US
dc.identifier.issn1471-2407
dc.identifier.urihttps://dx.doi.org/10.1186/s12885-023-10662-3.
dc.identifier.urihttps://hdl.handle.net/20.500.12933/1469
dc.description.abstractBackground There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.en_US
dc.language.isoengen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionof10.1186/s12885-023-10662-3.en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleCorrection: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapyen_US
dc.typearticleen_US
dc.authorid0000-0003-1235-9363en_US
dc.departmentAFSÜen_US
dc.contributor.institutionauthorDemir, Hacer
dc.identifier.volume23en_US
dc.identifier.issue1en_US
dc.relation.journalBMC Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster